Median age at biopsy (IQR), years
|
41 (36-45)
|
Male, n (%)
|
154 (84)
|
Ethnicity, n (%)
| |
Caucasian
|
163 (89)
|
Black
|
21 (11)
|
Intravenous drug use, n (%)
|
127 (61)
|
Alcohol use, n (%)*
|
67 (36)
|
Median duration of HIV diagnosis (IQR, years
|
11 (7-14)
|
Median CD4 cell counts/mm3 (IQR)
|
321 (227-461)
|
Undetectable HIV RNA+, n (%)
|
119 (67)
|
HCV genotype++, n (%)
| |
1
|
98 (55)
|
2
|
10 (6)
|
3
|
47 (26)
|
4
|
24 (13)
|
Median HCV RNA (IQR), log10 KIU/ml+++
|
6.18 (5.76-6.60)
|
Median laboratory variables (IQR), U/l
| |
ALT
|
83 (47-128)
|
AST
|
65 (43-97)
|
Alkaline phosphatase
|
89 (71-113)
|
GGT
|
80 (42-160)
|
Median glycemia (IQR), mmol/l
|
4.8 (4.3-5.3)
|
Glycemia 5.6mmol/l+, n (%)
|
33 (19)
|
Glycemia7.0mmol/l+, n (%)
|
7 (4)
|
Median total cholesterol (IQR), mmol/l
|
4.20 (3.54-5.10)
|
Median triglyceridemia (IQR), mmol/l
|
1.49 (0.99-2.10)
|
Triglyceridemia 1.7mmol/l+, n (%)
|
60 (36)
|
Median duration of antiretroviral therapy (IQR), months
|
58 (28-94)
|
Median cumulative exposure to antiretrovirals (IQR), months
| |
NRTI
|
56 (28-90)
|
NNRTI
|
16 (9-31)
|
PI
|
23 (12-40)
|
Combination of ART at liver biopsy, n (%)
| |
2 NRTI+1 PI
|
93 (51)
|
2 NRTI+1 NNRTI
|
36 (20)
|
1 or 2 NRTI
|
31 (16)
|
3 NRTI
|
17 (9)
|
Other regimens
|
7 (4)
|